Chronic Cyclooxygenase-2 Inhibition Promotes Myofibroblast-Associated Intestinal Fibrosis
Open Access
- 1 March 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 3 (3) , 348-358
Abstract
Anti-inflammatory drugs prevent intestinal tumor formation, an activity related to their ability to inhibit inflammatory pathway signaling in the target tissue. We previously showed that treatment of Min/+ mice with the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib induced rapid tumor regression; however, drug-resistant tumors appeared with long-term treatment. In this study, we investigated whole-tissue changes in inflammatory signaling by studying constituents of the tissue stroma and extracellular matrix. We found that celecoxib resistance was associated with changes in factors regulating autocrine transforming growth factor-β (TGFβ) signaling. Chronic drug treatment expanded the population of bone marrow–derived CD34+ vimentin+ αSMA− myofibroblast precursors and αSMA+ vimentin+ F4/80− myofibroblasts in the lamina propria and submucosa, providing a source of increased TGFβ and COX-2 expression. Membrane constituents regulating TGFβ availability, including syndecan-1 and heparanase-1, were also modified by chronic treatment in a manner promoting increased TGFβ signaling. Finally, long-term celecoxib treatment induced tissue fibrosis, as indicated by increased expression of collagen, fibronectin, and laminin in the basement membrane. We conclude that chronic COX-2 inhibition alters TGFβ signaling in the intestinal mucosa, producing conditions consistent with chronic inflammation. Cancer Prev Res; 3(3); 348–58Keywords
All Related Versions
This publication has 43 references indexed in Scilit:
- Oxidative Stress Alters Syndecan-1 Distribution in Lungs with Pulmonary FibrosisJournal of Biological Chemistry, 2009
- Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-βBritish Journal of Cancer, 2007
- NF-κB Is a Negative Regulator of IL-1β Secretion as Revealed by Genetic and Pharmacological Inhibition of IKKβCell, 2007
- Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathwaysProceedings of the National Academy of Sciences, 2007
- Celecoxib for the Prevention of Colorectal Adenomatous PolypsNew England Journal of Medicine, 2006
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Myofibroblasts and mechano-regulation of connective tissue remodellingNature Reviews Molecular Cell Biology, 2002
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000